Type III hypersensitivity is one of those Step 1/2 topics that feels “easy” until a question asks you to pick the best mechanism—and suddenly every answer choice looks kind of plausible. The trick is learning to translate the vignette into pathophys + timing + location of injury, then using that to actively eliminate distractors.
Tag: Immunology > Hypersensitivity Reactions
The Clinical Vignette (Q-bank style)
A 24-year-old woman is treated with IV ceftriaxone for pyelonephritis. Seven days later, she develops fever, urticarial rash, arthralgias, and malaise. Exam shows diffuse wheals and mild joint tenderness. Labs show low serum C3 and C4. Urinalysis is normal. Symptoms improve with discontinuation of the drug and NSAIDs.
Question: What is the most likely underlying mechanism?
Correct Answer: Type III (Immune Complex–Mediated) Hypersensitivity
Why it’s Type III
This vignette screams serum sickness / serum sickness–like reaction:
- Timing: typically 1–2 weeks after first exposure (can be faster with re-exposure)
- Symptoms: fever + urticarial rash + arthralgias (± lymphadenopathy)
- Complement: low C3/C4 due to consumption
- Trigger: classically foreign proteins/antiserum, but many drugs can cause serum sickness–like disease (e.g., cephalosporins, penicillins, sulfonamides)
Core mechanism (what you should picture)
- Soluble antigen (drug or drug-protein complex) persists in circulation.
- Body makes IgG (or IgM) antibodies.
- Immune complexes form in the blood and deposit in tissues (especially where filtration/turbulence occurs).
- Immune complexes activate classical complement → C3a/C5a (anaphylatoxins) → recruit neutrophils.
- Neutrophils attempt phagocytosis but can’t fully clear deposited complexes → “frustrated phagocytosis” → release ROS/enzymes → tissue injury.
High-yield tissue targets (Step pattern recognition)
Type III injury likes:
- Blood vessels → vasculitis, palpable purpura
- Glomeruli → hematuria/proteinuria (not present here, but classic in other Type III diseases)
- Joints → arthralgias/arthritis
- Skin → urticaria/purpura
The High-Yield “Type III Clues” Checklist
If you see these, move Type III to the top:
- Delayed onset after exposure (often ~7–14 days)
- Low complement (C3/C4 down)
- Neutrophil-driven inflammation
- Systemic symptoms: fever, arthralgia, rash
- Deposition diseases: serum sickness, Arthus reaction, SLE, PSGN, IgA vasculitis
Why Every Distractor Matters (Systematic Elimination)
Below are common answer choices that show up with this exact vignette—here’s how to kill them quickly.
Distractor A: Type I hypersensitivity (IgE-mediated mast cell degranulation)
Why it’s tempting: Urticaria shows up in both Type I and serum sickness.
Why it’s wrong here:
- Timing mismatch: Type I is minutes to hours after exposure.
- Complement levels are not classically low in Type I.
- Type I features: wheezing/bronchospasm, angioedema, anaphylaxis, pruritus—often immediate.
Board tip: Urticaria alone isn’t enough—timing + complement usually clinches it.
Distractor B: Type II hypersensitivity (antibody against cell surface/ECM)
Why it’s tempting: Drug reactions can involve antibodies, and hemolysis is a classic drug-related immune problem.
Why it’s wrong here:
- Type II targets fixed antigens (e.g., RBC membranes, basement membrane), not soluble antigens.
- Would expect cell-specific findings: hemolytic anemia, thrombocytopenia, nephritis with anti-GBM, etc.
- Complement can be involved in Type II, but the clinical pattern is usually more targeted (e.g., anemia) than systemic immune-complex symptoms.
High-yield Type II examples to keep separate:
- Autoimmune hemolytic anemia
- ITP
- Goodpasture syndrome (linear IF)
- Myasthenia gravis (receptor blockade)
- Graves disease (receptor stimulation)
Distractor C: Type IV hypersensitivity (T cell–mediated, delayed-type)
Why it’s tempting: The word “delayed” shows up and the rash seems plausible.
Why it’s wrong here:
- Type IV occurs 48–72 hours after exposure (classic contact dermatitis) or weeks for granulomatous inflammation—but it is T-cell mediated, not immune complexes.
- Type IV doesn’t classically cause low complement.
- Type IV skin findings are usually eczema-like (contact dermatitis) or indurated (PPD test), not the serum sickness triad.
High-yield Type IV examples:
- Poison ivy (urushiol)
- Nickel allergy
- PPD test
- Granulomas (TB, sarcoid)
Distractor D: Direct mast cell activation via C3a and C5a (“anaphylatoxins”)
Why it’s tempting: This is actually part of Type III, so it sounds right.
How to handle it:
- If the question asks for the overall mechanism, choose immune complex deposition with complement activation and neutrophil-mediated injury.
- If the question asks specifically what causes urticaria/edema, C3a/C5a–mediated mast cell degranulation can be a correct detail—but it’s not the primary pathologic category.
Exam strategy: Decide whether the stem wants the category (Type III) or a substep (C3a/C5a effects).
Distractor E: Granule release by eosinophils and mast cells
Why it’s tempting: Allergic conditions often involve eosinophils.
Why it’s wrong here:
- Eosinophils are central in Type I (and some parasitic infections).
- Type III is primarily neutrophils + complement.
- Eosinophilia can occur in some drug reactions, but it’s not the classic driver of serum sickness.
Distractor F: Immune complex deposition in glomeruli causing hematuria
Why it’s tempting: That’s a classic Type III consequence.
Why it might be wrong in this vignette:
- It’s too narrow: serum sickness is systemic (skin/joints ± kidneys).
- The urinalysis is normal, so kidney deposition isn’t featured in this particular stem.
- If UA had RBC casts/proteinuria, this distractor could become correct depending on question phrasing.
Takeaway: Type III can hit glomeruli, but not every Type III vignette includes nephritis.
Quick Comparison Table: Hypersensitivity Types (USMLE-focused)
| Type | Immune mediator | Timing | Key pathology | Classic examples |
|---|---|---|---|---|
| I | IgE → mast cells, eosinophils | Minutes | Histamine, leukotrienes | Anaphylaxis, allergic rhinitis, asthma, urticaria |
| II | IgG/IgM vs fixed antigen | Hours–days | Opsonization, complement, receptor effects | AIHA, Goodpasture, Graves, myasthenia |
| III | Immune complexes (IgG/IgM) | Days–weeks | Complement ↓, neutrophils, vasculitis | Serum sickness, Arthus, SLE, PSGN, IgA vasculitis |
| IV | T cells (Th1/Th17, CD8+) | 48–72h (or chronic) | Macrophage activation/cytotoxicity | Contact dermatitis, PPD, granulomas |
High-Yield Add-ons You’ll Actually Use on Test Day
Serum sickness vs serum sickness–like
- Serum sickness (classic): foreign proteins (e.g., antitoxins, antivenom); immune complexes; complement consumption.
- Serum sickness–like: drugs (e.g., cefaclor historically, other beta-lactams); similar symptoms; may have less dramatic immune complex evidence, but boards often treat them similarly—use timing + low complement.
Arthus reaction (localized Type III)
- Occurs hours after antigen injection in a sensitized person.
- Local immune complex deposition → edema, hemorrhage, necrosis.
- Think: tetanus booster with big swollen painful arm.
What “low complement” is trying to tell you
Classical complement pathway activation consumes complement:
- , often = immune complex disease (Type III) or SLE flare.
Final Takeaway (How to Pick the Right Answer Fast)
When you see 7–14 days after exposure + fever/rash/arthralgias + low C3/C4, default to:
- Type III hypersensitivity: immune complexes depositing → complement activation → neutrophil-mediated injury.
Then use timing and “soluble vs fixed antigen” to eliminate Type I/II/IV distractors.